Mutation Yield of a 34-Gene Solid Tumor Panel in Community-Based Tumor Samples

Sanders, Heather; Qu, Kevin; Li, Hairong; Ma, Lin; Barlan, Cindy; Zhang, Xi; Prentice, James; Wolfson, David B.; Crossley, Beryl; Sferruzza, Anthony; Sninsky, John J.; Ross, David A.; Grupe, Andrew; Catanese, Joseph J.; Hantash, Feras M.; Waldman, Frederic M.

doi:10.1007/s40291-016-0197-0

Cited by 1 publication

(1 citation statement)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… Breast cancer MammaPrint Agendia Yes 70 29 Prosigna NanoString Tech. 50 33 GeneSearch BLN test Veridex 2 30 INFORM HER2 Dual ISH Ventana 1 32 HER2 CISH pharmDx Kit Dako 1 31 Oncotype Dx Genomic Health No 21 34 EndoPredict Sividon Diagnostics 11 35 Breast Cancer Index test BioTheranostics 7 36 FEMTELLE Sekisui Diagnostics 2 37 Lung cancer Therascreen EGFR RGQ PCR kit QIAGEN Yes 1 40 cobas EGFR Mutation Test Roche 1 38 VENTANA ALK (D5F3) CDx Assay Ventana Medical Systems 1 41 Vysis ALK Break Apart FISH Probe Kit Abbott Molecular 1 39 Lung Cancer Mutation Panel Quest Diagnostics No 34 42 Lung Cancer Comprehensive Mutation and Translocation Panel ...…”

Section: Precision Oncology For Patients—from Precision Diagnosis To mentioning

confidence: 99%

Addressing the challenges of applying precision oncology

2017

View full text Add to dashboard Cite

Precision oncology is described as the matching of the most accurate and effective treatments with the individual cancer patient. Identification of important gene mutations, such as BRCA1/2 that drive carcinogenesis, helped pave the way for precision diagnosis in cancer. Oncoproteins and their signaling pathways have been extensively studied, leading to the development of target-based precision therapies against several types of cancers. Although many challenges exist that could hinder the success of precision oncology, cutting-edge tools for precision diagnosis and precision therapy will assist in overcoming many of these difficulties. Based on the continued rapid progression of genomic analysis, drug development, and clinical trial design, precision oncology will ultimately become the standard of care in cancer therapeutics.

show abstract